Pediatric Immune Gene Panels: What to Gather Before Testing

It reflects how heterogeneous these referrals are — and how much usable clinical information is available before the sample reaches the laboratory.

In pediatric immunology, the blood draw is usually the easiest part. The harder work happens beforehand: establishing whether the child has a pattern of immune dysfunction, deciding which biological systems are involved, checking whether the specimen will represent the child’s own germline DNA, and identifying any immediate safety issues while the diagnosis is still unresolved.

More than 500 distinct monogenic inborn errors of immunity have been described. Their presentations overlap, but they do not overlap neatly. Recurrent infections may point toward an antibody deficiency, a combined defect, a phagocyte disorder, or a problem with antiviral immunity. Eczema may be an allergic disease, a feature of a hyper-IgE syndrome, or part of a broader immune dysregulation phenotype. A gene panel can analyze many possibilities at once, but it cannot replace the clinical reasoning that determines how its findings should be interpreted.

The pediatric immune deficiency genetic testing preparation pathway is therefore not a paperwork exercise. It is the process that turns a sequencing report into a clinically useful answer — or makes clear why the answer remains incomplete.

Baseline Immunological Profiling: The Essential Pre-Test Foundation

Before a pediatric immune gene panel makes clinical sense, the patient needs basic immunophenotyping data. Genetic testing does not replace screening laboratories. It complements them, and the screening results often determine which genes, pathways, or testing strategy deserve priority.

At a minimum, the referring team should assemble:

• A complete blood count with differential, including absolute neutrophil, lymphocyte, and eosinophil counts. The interpretation must be age-adjusted. A lymphocyte count that appears acceptable by adult standards may be concerning in an infant, particularly when the clinical history suggests a severe T-cell disorder.
• Quantitative serum immunoglobulins, including IgG, IgA, IgM, and, where clinically relevant, IgE. Results should be interpreted against age-specific reference ranges and in the context of replacement immunoglobulin, recent infection, protein loss, and other factors that can distort the picture.
• Lymphocyte subset enumeration by flow cytometry, commonly including CD3, CD4, CD8, CD19, and CD16/56 populations. The pattern is often more informative than a total lymphocyte count alone when the question is whether the child has a predominantly humoral, cellular, or combined defect.
• T-cell receptor excision circle testing, when severe combined immunodeficiency is being considered and the child is within the age range where the result is clinically informative. A positive newborn screen requires prompt follow-up; it is not a substitute for a diagnostic evaluation.
• Functional studies where indicated, such as lymphocyte proliferation, neutrophil oxidative burst testing, complement assessment, or vaccine-specific antibody responses. These tests are not required for every child, but they can be decisive when the phenotype points toward a functional defect that sequencing alone may not settle.

The timing of these tests matters. Acute illness can temporarily change blood counts and lymphocyte distributions. Recent corticosteroid exposure may suppress or alter cellular measurements. Immunoglobulin replacement can complicate interpretation of antibody levels. A result obtained during a severe infection may still be clinically important, but the report should say what was happening when the sample was collected.

The same principle applies to vaccine responses. A low or absent antibody response may reflect an immune defect, incomplete vaccination, an interval that is too short for interpretation, or passive immunoglobulin administration. The laboratory and immunology team need the dates and treatment context, not just the numerical result.

Without this foundation, a variant of uncertain significance is almost impossible to place properly. A laboratory may identify a rare change in a gene associated with immune disease, but the clinical team still has to ask whether the child’s cellular phenotype, immunoglobulin pattern, infection history, and functional testing support that mechanism. Genetic data become much more useful when they can be tested against a defined immunological phenotype.

A gene panel is a hypothesis-testing tool, not a substitute for the first round of immunology. Run the foundational assays, then give the sequencing result something clinical to attach to.

Mapping the Clinical Phenotype: Why Detailed History Drives Diagnostic Success

The molecular test is only as specific as the phenotype behind it. A referral that says recurrent infections provides very little information. A referral that records the organisms, sites, age at onset, treatment response, complications, and periods of wellness gives the laboratory a workable diagnostic map.

I want the following documented before the order goes in.

• Infection history with specifics. Record the age at first infection, the number and type of episodes, anatomic sites, identified organisms, hospitalization, intensive care, unusual complications, antimicrobial response, and whether the child returns fully to baseline between episodes. Pneumonia caused by an encapsulated bacterium raises a different question from persistent mucocutaneous candidiasis, invasive fungal disease, disseminated mycobacterial infection, or severe viral illness.
• Age at presentation. Early infancy is not simply a more dramatic version of later childhood. Infections in the first months of life, persistent thrush, failure to thrive, chronic diarrhea, or opportunistic infection may move severe T-cell or combined immunodeficiency much higher on the differential.
• Autoimmune and autoinflammatory features. Cytopenias, vasculitis, inflammatory bowel disease-like symptoms, unexplained fever, splenomegaly, lymphoproliferation, and severe early-onset autoimmune disease can indicate immune dysregulation rather than a straightforward failure to produce antibodies. These details may redirect analysis toward conditions associated with genes such as LRBA or CTLA4, among others.
• Allergic and atopic features. Severe refractory eczema, food allergy, anaphylaxis, persistent eosinophilia, asthma that is unusually severe for age, and recurrent skin or lung infections should be recorded together. The combination can be more informative than any single feature and may support investigation of disorders involving pathways associated with DOCK8, PGM3, STAT3, and other genes.
• Viral susceptibility and malignancy. EBV-driven lymphoproliferation, severe or persistent HPV disease, unusual herpesvirus infections, lymphoma, or other malignancy may point toward defects in viral control, immune surveillance, or DNA repair.
• Growth and organ involvement. Growth failure, chronic lung disease, bronchiectasis, enteropathy, liver disease, renal findings, skeletal abnormalities, neurologic features, and developmental concerns can distinguish a syndromic disorder from an isolated immune phenotype.
• Physical findings. Document lymph node and spleen size, skin findings, dysmorphic features, telangiectasia, pigmentary changes, nail abnormalities, and signs of chronic infection. A photograph may be useful in the clinical record when permitted by local policy, especially if a rash or swelling changes over time.
• Medication and treatment history. Include corticosteroids, biologic therapies, immunosuppressants, antimicrobial prophylaxis, immunoglobulin replacement, and any treatment that could alter immune measurements or infection risk.
• Family history across generations. Ask about consanguinity, early childhood deaths, recurrent severe infections, unexplained inflammatory disease, autoimmune disease, malignancy, developmental disorders, and similar findings in siblings, half-siblings, cousins, or grandparents. A negative family history does not exclude a recessive or de novo condition, but a carefully drawn pedigree can change the testing strategy.
• Parental and sibling availability. If trio exome sequencing or segregation analysis may be needed, document whether both biological parents and relevant relatives are available for testing. This is a practical detail with major interpretive consequences.

A pediatric genetic test phenotyping checklist should not be treated as a form to complete after the blood has been drawn. It is a way of forcing the clinical story into a form that can be compared with known disease mechanisms. The most useful history is not the longest one; it is the one that distinguishes recurrent ordinary childhood infections from infections that are unusually severe, persistent, invasive, treatment-resistant, or accompanied by immune dysregulation.

There is also a difference between a phenotype that is absent and one that has not been assessed. If the child has not had a particular infection, that may be meaningful. If nobody has asked about chronic diarrhea, oral ulcers, warts, skeletal findings, or reactions to live vaccines, the chart should say that the feature was not reported or not evaluated rather than calling it negative.

For relatives, use the same discipline. “No family history” often means that no one has constructed a family history. Ask who was affected, at what age, with what diagnosis, and whether deaths or infertility were ever medically explained.

Navigating Sample Integrity: Avoiding Pitfalls in Post-Transplant Patients

This is where some of the most avoidable pre-analytical errors occur in pediatric immune deficiency genetic testing preparation.

The key question is not merely which test to order. It is whether the specimen will contain the patient’s germline DNA. After an allogeneic hematopoietic stem cell or bone marrow transplant, blood-forming cells may be donor-derived. A peripheral-blood sample can therefore reflect the donor’s genotype rather than the child’s inherited DNA. That is a problem when the purpose of testing is to identify the original germline cause of the immune disorder.

The same concern applies to bone marrow and, depending on the circumstances, saliva or buccal samples. These sources can contain a substantial contribution from donor-derived or other non-host cells. A result may look technically clean while answering the wrong biological question.

A common scenario is a child who received an allogeneic transplant for suspected or confirmed severe combined immunodeficiency and is now clinically stable. A clinician orders a later “confirmatory” panel from peripheral blood because the original diagnosis was not fully documented. If chimerism and specimen suitability are not reviewed first, the sequencing may represent the donor rather than the child.

For patients with a history of allogeneic transplantation:

• Confirm the transplant history before ordering. Record the type of transplant, donor relationship and source, date of transplantation, conditioning where relevant, and available chimerism results.
• Ask the laboratory which tissue is acceptable. Cultured skin fibroblasts or another validated non-hematopoietic source may be required for germline analysis. The laboratory should approve the specimen plan before collection.
• Explain the additional timeline to the family. A skin biopsy and fibroblast culture are more involved than a routine blood draw, and culture time may add weeks before sequencing can begin.
• Do not assume that a negative blood-based result is reassuring. If the specimen is not representative of the patient’s germline, a negative or unexpected result may be uninterpretable rather than clinically reassuring.
• Review prior genetic testing. The original transplant records, newborn screening follow-up, stored samples, family testing, and previous molecular reports may be more informative than repeating an unsuitable specimen.

In non-transplant patients, saliva and buccal swabs still require attention to collection instructions. Recent food or drink, poor epithelial sampling, and blood contamination from oral lesions can reduce sample quality. A recent transfusion should also be disclosed, because donor leukocytes may complicate interpretation in some circumstances. The laboratory’s own collection requirements should take precedence over a generic assumption about which sample is acceptable.

For standard blood-based NGS panels, the requisition should specify the tube type, minimum volume, and handling requirements requested by that laboratory. An underfilled or improperly transported tube may be rejected before sequencing begins. That adds a logistical delay at exactly the point when the clinical team may be waiting to make decisions about prophylaxis, vaccination, or further functional testing.

A rejected specimen is not just an administrative annoyance. In a child being evaluated for a potentially serious immune defect, every repeat collection creates another delay and another opportunity for the clinical team and family to lose track of the safety plan.

Safety Protocols: Managing Vaccination Risks During the Diagnostic Window

The most sensitive period is the interval between raising concern for a serious immune disorder and establishing whether the child has a severe T-cell or combined immunodeficiency. The vaccination plan during that interval should be explicit, individualized, and coordinated with a pediatric immunologist.

Live-attenuated vaccines require particular caution when severe T-cell or combined immunodeficiency is suspected. Depending on age and local schedule, these may include rotavirus, measles-mumps-rubella, varicella, and live attenuated influenza vaccine. The concern is not limited to the moment of genetic testing. It relates to the child’s immune function, which may not yet be adequate to control a live vaccine strain.

This restriction should not be broadened to every child with a possible immune problem. Suspected isolated antibody deficiency, for example, is not automatically managed in the same way as suspected severe T-cell or combined immunodeficiency. The appropriate action depends on the phenotype, laboratory findings, age, vaccine, and specialist assessment.

The preparation process should therefore include:

• A documented review of live vaccines if severe T-cell or combined immunodeficiency is on the differential. If a dose is due, contact the immunology team before administration. Do not rely on an informal verbal message that may not reach the primary-care or vaccination team.
• A clear family-facing instruction. Parents should know which vaccines are being deferred, why the deferral is temporary or under review, and whom to contact before an appointment at another clinic.
• Continuation of non-live vaccines when clinically appropriate. Inactivated or recombinant vaccines are generally approached differently from live vaccines, but the plan still needs to account for the child’s age, current illness, prior doses, immunoglobulin replacement, and the possibility of a poor response.
• Coordination with the laboratory and immunology service. Turnaround time matters, but a genetic report alone may not answer whether vaccination is safe. Functional immune assessment and clinical review may be required.
• A plan for exposure and infection risk. While testing is pending, the family may need advice about sick contacts, fever, urgent assessment, and what symptoms should prompt immediate medical attention.

A live-vaccine hold should not be described as a blanket response to the phrase immunodeficiency. It is a targeted safety measure for situations in which a severe cellular or combined defect remains a realistic concern. Conversely, once that concern is present, the hold should be written down clearly enough that it survives handoffs between specialists, primary care, and vaccination services.

A negative panel does not restore immune function. Nor does it necessarily exclude a disorder that the panel could not detect. Decisions about live vaccines should be based on the whole clinical and immunological assessment, not on the word negative at the top of a sequencing report.

Sequencing can identify a cause, but it cannot by itself prove that a child can safely handle a live vaccine. That decision belongs to the clinical assessment of immune function.

Interpreting the Yield: Setting Realistic Expectations for NGS Panels

The reported 15% to 46% diagnostic yield for NGS panels in primary immunodeficiency is useful only when its limits are understood. Different studies use different referral criteria, panel designs, phenotype definitions, and standards for calling a result diagnostic. A number from one cohort should not be presented as a guarantee for an individual child.

A negative panel does not rule out inborn error of immunity. Potential explanations include a disease-causing change that the assay did not detect, a copy-number or structural variant outside the test’s validated range, a non-coding alteration, a gene not yet linked to disease, or a clinical diagnosis that depends on a functional abnormality not captured by the panel. Technical limitations and sample problems must also be considered, particularly after transplantation.

The next step after a negative result should follow the phenotype rather than the marketing language attached to the test. The team may need to:

1. Review whether the original phenotype still fits an immune disorder. Some children accumulate ordinary infections during early childhood, while others develop a clearer pattern over time.

2. Check whether the right specimen was tested. This is essential after allogeneic transplantation and whenever the laboratory raised a quality or contamination concern.

3. Revisit the laboratory methods. Ask whether the panel included the relevant genes, deletion and duplication analysis, structural variant detection, and the regions needed for the suspected condition.

4. Complete or repeat targeted functional testing. A biochemical or cellular assay may point toward a mechanism that was not visible in the first sequencing analysis.

5. Discuss broader testing. Trio exome sequencing, with both biological parents as comparators, can be useful when the phenotype is broad or the panel is unrevealing. Whole-genome sequencing may be considered when the clinical suspicion remains high and panel or exome testing has not resolved the case.

6. Plan for reinterpretation. Variant databases and disease-gene knowledge change. A result that is uninformative today may become relevant after new evidence, but reinterpretation works best when the original phenotype and family data were documented carefully.

A VUS is not a diagnosis. It may eventually become important, particularly if it segregates with disease in the family or matches the child’s functional phenotype, but it should not be used on its own to label a child with a specific immune disorder or to make irreversible treatment decisions. The laboratory may request parental samples, additional clinical information, or functional studies. That is not a sign that the test failed; it is part of responsible variant interpretation.

The converse problem also matters. A pathogenic variant can be misleading if it does not fit the child. A change in a gene associated with immune disease deserves attention, but the team still has to establish whether the inheritance pattern, zygosity, phenotype, laboratory findings, and clinical course are coherent. The report is a piece of the diagnosis, not the diagnosis in isolation.

Families should also receive a realistic explanation of what the test can and cannot deliver. The immediate outcome may be a molecular diagnosis, a result requiring further work, or no confirmed genetic explanation. Each outcome carries a different follow-up plan. The absence of a molecular answer does not make the child’s infections or inflammatory symptoms less real, and it does not end clinical surveillance when the phenotype remains concerning.

The Realistic Verdict

A pediatric immune gene panel ordered without baseline immunology, a documented multi-system phenotype, transplant review, and a clear safety plan is being asked to do too much. The sequencing platform may be technically capable, but the interpretation will still be constrained by what was known — and what was not recorded — before the sample was collected.

For a child being referred for evaluation, the useful preparation is concrete:

• CBC with differential, interpreted for age;
• quantitative immunoglobulins and relevant functional studies;
• lymphocyte subsets, with TREC follow-up when appropriate;
• an infection timeline that names organisms, sites, severity, and treatment response;
• review of autoimmune, inflammatory, allergic, growth, skin, lung, gastrointestinal, and neurologic features;
• a family history that extends beyond the parents;
• vaccination and current medication review;
• confirmation of transfusion and transplant history;
• a specimen plan approved by the laboratory;
• and a documented approach to live vaccines when severe T-cell or combined immunodeficiency remains a concern.

This is what to gather before a pediatric genetic panel: not a thicker requisition, but a better clinical model of the child. The same information helps the laboratory prioritize variants, helps the immunologist choose functional tests, and helps the family understand why a result may be diagnostic, uncertain, or incomplete.

Three milliliters of blood may be the easy part. The clinical reasoning around it is where the work actually lives.